<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03142178</url>
  </required_header>
  <id_info>
    <org_study_id>3VM1216</org_study_id>
    <nct_id>NCT03142178</nct_id>
  </id_info>
  <brief_title>3VM for Treatment of Chronic Osteoarthritis Knee Pain</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety and Efficacy of 3VM1001 Cream for the Treatment of Chronic Pain Caused by Osteoarthritis of the Knee: A Dose Ranging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CDA Research Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CDA Research Group, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, placebo-controlled, randomized dose ranging study for the use of 3VM1001&#xD;
      Cream, 2g three times daily, 3g three times daily, or 3g four times daily for treatment of&#xD;
      chronic pain associated with osteoarthritis of the knee compared to inactive placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a double-blind, placebo-controlled, dose ranging study for the use of 3VM1001&#xD;
      Cream, 2g three times daily, 3g three times daily, or 3g four times daily for the treatment&#xD;
      of chronic pain associated with osteoarthritis of the knee compared to the inactive vehicle&#xD;
      as a placebo.&#xD;
&#xD;
      A maximum of 120 subjects will be enrolled. Subjects will self-treat for 7 (+2) days, applied&#xD;
      in the morning and at bed time.&#xD;
&#xD;
      The active pharmaceutical ingredient is copper. The proposed doses in the study are less than&#xD;
      2% of the upper limit of the RDA (0.9 mg/day, upper limit 10mg/day).&#xD;
&#xD;
      Rescue medication is acetaminophen, up to ~2g daily (Up to six Tylenol Regular Strength&#xD;
      tablets).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 30, 2017</start_date>
  <completion_date type="Actual">June 1, 2018</completion_date>
  <primary_completion_date type="Actual">January 30, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, placebo controlled, randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Participant, Investigator</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time averaged change from baseline in a standard 100 mm Visual Analog Scale (VAS).</measure>
    <time_frame>7 days</time_frame>
    <description>The time-averaged mean of all patient pain scores over each study period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events, Serious adverse events, and study discontinuation</measure>
    <time_frame>8 days</time_frame>
    <description>Collection of Adverse events, Serious adverse events, and study discontinuation over each study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global impression of change scale (PGIC) from baseline to end of study period.</measure>
    <time_frame>8 days</time_frame>
    <description>This measure is a single-item rating by participants of their improvement with treatment on a 7-point scale that ranges from &quot;very much improved&quot; to &quot;very much worse&quot; with a mid-point of &quot;no-change&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the global rating of disease for 3VM1001 Cream and placebo from baseline to the end of study.</measure>
    <time_frame>8 days</time_frame>
    <description>Change in the global rating of disease for 3VM1001 Cream and placebo from baseline to day 8 measured on a 5-point Likert scale, with numerical values recorded by the subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of change from baseline in Osteoarthritis (OA) pain..</measure>
    <time_frame>From screening Day 0 to the end of study (8 days)</time_frame>
    <description>Subjects will rate their overall satisfaction from baseline (Day 0) to the end of study using a 6-point categorical sale from &quot;very much worse&quot;(0) to &quot;very satisfied&quot; (6).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Global Assessment of Treatment Satisfaction from baseline to end of study.</measure>
    <time_frame>8 days</time_frame>
    <description>Subjects will rate their overall satisfaction with study treatment using a 5-point categorical sccale from &quot;dissatisfied&quot; (0) to &quot;very satisfied&quot; (4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication</measure>
    <time_frame>8 days</time_frame>
    <description>The use of rescue medication for pain</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Arthritis, Degenerative</condition>
  <arm_group>
    <arm_group_label>Experimental 3VM1001 2g X 3 daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3VM1001 active cream administered 2g cream three times daily for seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo; 3VM1001 vehicle 2g X 3 daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3VM1001 placebo vehicle administered 2g cream three times daily for seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 3VM1001 3g X 3 daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3VM1001 active cream administered 3g cream three times daily for seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo; 3VM1001 vehicle 3g X3 daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3VM1001 placebo vehicle administered 3g cream three times daily for seven day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 3VM1001 3g x 4 daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3VM1001 active cream administered 3g cream four times daily for seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo; 3VM1001 vehicle 3g X 4 daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3VM1001 placebo vehicle administered 3g cream four times daily for seven days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: 3VM1001 active 2g Cream 3 times daily</intervention_name>
    <description>3VM1001 2g Cream with active ingredient administered 3 times daily</description>
    <arm_group_label>Experimental 3VM1001 2g X 3 daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: 3VM1001 active 3g Cream 3 times daily</intervention_name>
    <description>3VM1001 3g Cream with active ingredient administered 3 times daily</description>
    <arm_group_label>Experimental 3VM1001 3g X 3 daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: 3VM1001 active 3g Cream 4 times daily</intervention_name>
    <description>3VM1001 3g Cream with active ingredient administered 4 times daily</description>
    <arm_group_label>Experimental 3VM1001 3g x 4 daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo: 3VM1001 vehicle 2g Cream 3 times daily</intervention_name>
    <description>3VM1001 placebo 2g vehicle Cream administered 3 times daily</description>
    <arm_group_label>Placebo; 3VM1001 vehicle 2g X 3 daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo: 3VM1001 vehicle 3g Cream 3 times daily</intervention_name>
    <description>3VM1001 placebo 3g vehicle Cream administered 3 times daily</description>
    <arm_group_label>Placebo; 3VM1001 vehicle 3g X3 daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo: 3VM1001 vehicle 3g Cream 4 times daily</intervention_name>
    <description>3VM1001 placebo 3g vehicle Cream administered 4 times daily</description>
    <arm_group_label>Placebo; 3VM1001 vehicle 3g X 4 daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Osteoarthritis of the knee according to American College of Rheumatology clinical&#xD;
             radiological criteria. A knee radiograph will be ordered and reviewed.&#xD;
&#xD;
          -  OA of the knee &gt;/= 6 months prior to screening. Subjects with OA of both knees will&#xD;
             treat the worst knee.&#xD;
&#xD;
          -  Age 40 years or older&#xD;
&#xD;
          -  Males or females of non-childbearing potential (12 or more months of spontaneous&#xD;
             amenorrhea, bilateral oophorectomy at least 6 months prior to randomization,&#xD;
             hysterectomy with bilateral oophorectomy at least 6 months prior to randomization, or&#xD;
             for females over 50 years of age, hysterectomy without bilateral oophorectomy at least&#xD;
             6 months prior to randomization.; female subjects of childbearing potential must agree&#xD;
             to use contraception (abstinence, birth control pills, rings or patches, diaphragm an&#xD;
             spermicide, intrauterine device, condom and vaginal spermicide, surgical&#xD;
             sterilization, vasectomy, progestin implant or injection); female partners of&#xD;
             childbearing potential of male subjects must agree to use contraception as defined&#xD;
             above.&#xD;
&#xD;
          -  Moderate to severe OA pain defined a POM score between 40 mm and 90 mm.&#xD;
&#xD;
          -  Baseline WOMAC pain subscale score &gt;/=9.&#xD;
&#xD;
          -  No change in physical activity and/or therapy for the past 3 months.&#xD;
&#xD;
          -  All concurrent medications taken for any reason stable for 14 days&#xD;
&#xD;
          -  Ability to follow protocol with reference to cognitive and situational factors such as&#xD;
             stable housing, ability to attend visits.&#xD;
&#xD;
          -  Ability to read and write English.&#xD;
&#xD;
          -  Ability to apply cream without assistance.&#xD;
&#xD;
          -  Able to provide written informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Presence of significant medical disorder that would compromise the participant's&#xD;
             safety to take part in the study such as cancer, immunosuppressed, or evidence of&#xD;
             alcohol or substance abuse.&#xD;
&#xD;
          -  Wilson's disease or other disorder of copper metabolism.&#xD;
&#xD;
          -  BMI &gt;40&#xD;
&#xD;
          -  Known hypersensitivity or allergy to any component of the product, or to&#xD;
             acetaminophen.&#xD;
&#xD;
          -  Transcutaneous electrical nerve stimulation and use of crutches, walkers or wheel&#xD;
             chairs should be excluded prior to and during treatment. Use of a cane is permitted.&#xD;
&#xD;
          -  Active conditions over the area to be treated such a eczema or psoriasis, compromised&#xD;
             integrity of the intact, superficial skin layer over the area to be treated.&#xD;
&#xD;
          -  Pain in any joint being studied that could interfere with the subject's assessment of&#xD;
             pain in the index joint.&#xD;
&#xD;
          -  Recent (within 12 months) injury (traumatic or sports related) to either knee causing&#xD;
             pain and interference with daily activities such as walking.&#xD;
&#xD;
          -  Recent (within 12 months) surgery/procedure (including intra-articular injection) to&#xD;
             either knee causing pain that could interfere with study assessments of pain,&#xD;
             function, and QoL.&#xD;
&#xD;
          -  Extreme pain in the target knee characterized by POM score of &lt;/= 40 mm.&#xD;
&#xD;
          -  Mild pain in the target knee characterized by POM score of &lt;/= 40 mm.&#xD;
&#xD;
          -  Open surgery of he target knee within the last year.&#xD;
&#xD;
          -  Significant concomitant disease of the knee to be studied such as fracture or&#xD;
             osteonecrosis.&#xD;
&#xD;
          -  Arthroscopic surgery of the target knee within the last 3 months.&#xD;
&#xD;
          -  Use of prohibited medications/therapies during he 7-9 day treatment period including:&#xD;
&#xD;
               1. Devices of therapeutics for knee pain or ambulation&#xD;
&#xD;
               2. Analgesics other than acetaminpohen&#xD;
&#xD;
               3. Systemic or locally injected corticosteroids&#xD;
&#xD;
               4. Other investigational drugs&#xD;
&#xD;
               5. Chemotherapy drugs&#xD;
&#xD;
               6. Immunotherapy&#xD;
&#xD;
               7. Topical products applied to he target knee&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Optimed Research, LTD</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>April 27, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2017</study_first_posted>
  <last_update_submitted>July 5, 2018</last_update_submitted>
  <last_update_submitted_qc>July 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>pain</keyword>
  <keyword>knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

